MCID: ESS003
MIFTS: 69

Essential Thrombocythemia

Categories: Blood diseases, Bone diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Essential Thrombocythemia

MalaCards integrated aliases for Essential Thrombocythemia:

Name: Essential Thrombocythemia 12 77 54 26 60 30 6 15 17
Essential Thrombocytosis 54 26 60 38
Hemorrhagic Thrombocythemia 12 54
Hereditary Thrombocythemia 12 60
Thrombocythemia, Essential 45 74
Familial Thrombocytosis 12 60
Primary Thrombocythemia 54 26
Primary Thrombocytosis 12 26
Essential Thrombocythaemia 12
Idiopathic Thrombocythemia 54
Thrombocythemia Essential 56
Familial Thrombocythemia 60
Et 60

Characteristics:

Orphanet epidemiological data:

60
essential thrombocythemia
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-5/10000 (United States),1-5/10000 (Sweden); Age of onset: All ages; Age of death: normal life expectancy;
familial thrombocytosis
Inheritance: Autosomal dominant,X-linked recessive; Age of onset: Childhood; Age of death: normal life expectancy;

Classifications:



Summaries for Essential Thrombocythemia

NIH Rare Diseases : 54 Essential thrombocythemia belongs to a group of diseases called myeloproliferative neoplasms, which cause the bone marrow to make too many platelets, white blood cells and/or red blood cells. In essential thrombocythemia, the body produces too many platelets. The signs and symptoms vary from person to person, but most people with essential thrombocythemia do not have any symptoms when the platelet cell count first increases. Signs and symptoms that develop as the disease progresses include:increased production of megakaryocytes (a type of cell in the bone marrow that is responsible for making platelets); enlargement of the spleen (splenomegaly); and bleeding in several parts of the body and/or clotting episodes such as strokes, pain in the legs and difficulty breathing. Other symptoms may include weakness, headaches, or a burning, tingling or prickling sensation in the skin. Some people have episodes of severe pain, redness, and swelling (especially in the hands and feet). Essential thrombocythemia may be caused by a person acquiring (not inheriting) a somatic mutation in any of several genes, such as the JAK2 gene (most frequently), CALR gene, and rarely, the MPL, THPO, or TET2 gene. The reason why some people acquire mutations that cause the disease is unknown. Treatment may include low-dose aspirin, hydroxyurea, anagrelide, and/or interferon-alpha. Most people with the disease can live long lives. In very rare cases, essential  thrombocythemia can transform into either primary myelofibrosis or acute myeloid leukemia.

MalaCards based summary : Essential Thrombocythemia, also known as essential thrombocytosis, is related to thrombocythemia 1 and thrombocytosis. An important gene associated with Essential Thrombocythemia is CALR (Calreticulin), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Hydroxyurea and Anagrelide have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and myeloid, and related phenotypes are myocardial infarction and abnormal bleeding

Disease Ontology : 12 A myeloproliferative neoplasm that is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage and that results in the overproduction of platelets.

Genetics Home Reference : 26 Essential thrombocythemia is a condition characterized by an increased number of platelets (thrombocythemia). Platelets (thrombocytes) are blood cell fragments involved in blood clotting. While some people with this condition have no symptoms, others develop problems associated with the excess platelets.

Wikipedia : 77 Essential thrombocythemia (ET) is a rare chronic blood condition characterised by the overproduction of... more...

Related Diseases for Essential Thrombocythemia

Diseases in the Essential Thrombocythemia family:

Thrombocythemia 1 Thrombocythemia 2
Thrombocythemia 3

Diseases related to Essential Thrombocythemia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 225, show less)
# Related Disease Score Top Affiliating Genes
1 thrombocythemia 1 33.4 CALR MPL SH2B3 THPO
2 thrombocytosis 32.6 EPO IL3 JAK2 MPL SELP TET2
3 acquired von willebrand syndrome 32.6 JAK2 VWF
4 myeloproliferative neoplasm 32.6 ABL1 CALR JAK2 MPL SH2B3 STAT5B
5 thrombosis 31.9 JAK2 SELP THBD VWF
6 polycythemia 31.8 CALR CD177 EPO IL3 JAK2 MPL
7 polycythemia vera 31.2 ABL1 CALR CD177 EPO IFNA1 IL3
8 myeloid leukemia 31.1 ABL1 IL3 JAK2 TET2 TP53
9 myeloma, multiple 31.0 EPO IFNA1 JAK2 TP53
10 stroke, ischemic 30.8 PPBP SELP THBD VWF
11 purpura 30.7 MPL THBD THPO VWF
12 splenomegaly 30.7 EPO IFNA2 JAK2 MPL
13 thrombocytopenic purpura, autoimmune 30.7 IFNA2 MPL SELP THPO
14 portal hypertension 30.6 JAK2 THPO VWF
15 antiphospholipid syndrome 30.6 SELP THBD VWF
16 thrombocytopenia due to platelet alloimmunization 30.6 MPL SELP THPO
17 hairy cell leukemia 30.5 IFNA1 IFNA2 IL3
18 peripheral vascular disease 30.5 PPBP SELP THBD VWF
19 vascular disease 30.5 PPBP SELP THBD VWF
20 thrombotic thrombocytopenic purpura 30.5 SELP THBD VWF
21 chromosome 5q deletion syndrome 30.4 EPO TET2
22 myelofibrosis 30.3 ASXL1 CALR CD177 EPO IFNA1 IFNA2
23 vasculitis 30.3 IFNA2 THBD VWF
24 chronic myelomonocytic leukemia 30.3 ASXL1 JAK2 TET2
25 refractory anemia 30.3 ASXL1 EPO IL3 JAK2 MPL TET2
26 systemic mastocytosis 30.3 ASXL1 IFNA2 JAK2 TET2
27 megakaryocytic leukemia 30.2 IL3 JAK2 THPO TP53 VWF
28 myelodysplastic syndrome 30.1 ABL1 ASXL1 EPO IL3 JAK2 MPL
29 erythrocytosis, familial, 1 30.1 EPO IL3 JAK2 SH2B3 STAT5B THPO
30 leukemia, acute myeloid 30.0 ABL1 ASXL1 IL3 JAK2 MIR223 MPL
31 aplastic anemia 29.8 ASXL1 EPO IL3 MPL TET2 THPO
32 acute promyelocytic leukemia 29.8 IL3 MIR223 STAT5B THBD
33 leukemia, chronic myeloid 29.7 ABL1 CD177 EPO IFNA1 IFNA2 IL3
34 bone marrow cancer 29.0 ABL1 CALR CD177 EPO IFNA1 IFNA2
35 thrombocythemia with distal limb defects 11.2
36 leukemia 10.8
37 myocardial infarction 10.6
38 subacute myeloid leukemia 10.6 JAK2 TET2
39 unilateral absence of a pulmonary artery 10.5 THBD VWF
40 thrombocytopenia 3 10.5 MPL THPO
41 thrombocytopenia-absent radius syndrome 10.5 CALR JAK2 MPL THPO
42 lymphomatoid granulomatosis 10.5 IFNA1 IFNA2
43 squamous papillomatosis 10.5 IFNA1 IFNA2
44 grange syndrome 10.5 SELP THBD VWF
45 primary thrombocytopenia 10.5 MPL SELP THPO VWF
46 autoimmune disease of blood 10.5 MPL SELP THPO VWF
47 dyskeratosis congenita, autosomal dominant 6 10.4 MPL THPO
48 colloid adenoma 10.4 PPBP TP53
49 lymphocytic leukemia 10.4
50 folic acid deficiency anemia 10.4 EPO TET2 THPO
51 acute erythroid leukemia 10.4 JAK2 TP53
52 amegakaryocytic thrombocytopenia, congenital 10.4 IL3 MPL THPO
53 acute myocardial infarction 10.4
54 blood platelet disease 10.4 JAK2 MPL SELP THPO VWF
55 cellular neurofibroma 10.4 ABL1 TP53
56 cryoglobulinemia, familial mixed 10.4 IFNA1 IFNA2
57 hemorrhagic disease 10.4 MPL PPBP THBD THPO VWF
58 behcet syndrome 10.4 IFNA1 IFNA2 JAK2 THBD
59 sm-ahnmd 10.4 ASXL1 TET2
60 hypertension, essential 10.3 PPBP SELP THBD VWF
61 leukemia, chronic lymphocytic 2 10.3
62 leukemia, chronic lymphocytic 10.3
63 ischemia 10.3
64 leukemia, b-cell, chronic 10.3
65 blood coagulation disease 10.3 JAK2 MPL SELP THBD THPO VWF
66 retinitis pigmentosa and erythrocytic microcytosis 10.3 EPO IL3 JAK2
67 conjunctival squamous cell carcinoma 10.3 IFNA2 TP53
68 maxillary sinus squamous cell carcinoma 10.3 CALR TP53
69 acute leukemia 10.3
70 thrombocytopenia 10.3
71 lymphoma 10.3
72 chronic leukemia 10.3 ASXL1 JAK2 STAT5B TET2
73 acquired polycythemia 10.3 EPO JAK2
74 neutropenia 10.3 CD177 IFNA1 IFNA2 IL3
75 qualitative platelet defect 10.3 SELP VWF
76 pancytopenia 10.3 EPO IL3 MPL THPO
77 atypical chronic myeloid leukemia 10.3 ABL1 ASXL1 JAK2
78 acquired immunodeficiency syndrome 10.3 EPO IFNA1 IFNA2 TP53
79 budd-chiari syndrome 10.3
80 erythromelalgia 10.3
81 anemia of prematurity 10.3 EPO IL3 STAT5B
82 myelodysplastic myeloproliferative cancer 10.3 ABL1 ASXL1 JAK2 TET2
83 heparin-induced thrombocytopenia 10.3
84 hypereosinophilic syndrome 10.2 ABL1 IFNA1 IL3
85 platelet aggregation, spontaneous 10.2 SELP VWF
86 sarcoma 10.2
87 myeloid sarcoma 10.2
88 diamond-blackfan anemia 10.2 EPO IL3 MPL THPO TP53
89 intracranial hypertension 10.2
90 platelet membrane fluidity 10.2
91 thrombophilia due to thrombin defect 10.2
92 leukemia, acute lymphoblastic 10.2
93 von willebrand's disease 10.2
94 acute biphenotypic leukemia 10.1
95 thrombophilia 10.1
96 pneumonia 10.1
97 priapism 10.1
98 thrombophilia due to activated protein c resistance 10.0
99 thrombocythemia 2 10.0
100 coronary heart disease 1 10.0
101 angina pectoris 10.0
102 deficiency anemia 10.0
103 acute lymphocytic leukemia 10.0
104 arthritis 10.0
105 hemolytic anemia 10.0
106 heart disease 10.0
107 coronary thrombosis 10.0
108 branch retinal artery occlusion 10.0
109 central retinal artery occlusion 10.0
110 renovascular hypertension 10.0
111 mastocytosis 10.0
112 placenta disease 10.0
113 retinal artery occlusion 10.0
114 carotid artery dissection 10.0
115 chromosomal triplication 10.0
116 hematologic cancer 10.0 ABL1 IL3 JAK2 MPL STAT5B TET2
117 limb ischemia 10.0
118 down syndrome 9.9
119 thrombocythemia 3 9.9
120 angiosarcoma 9.9
121 poems syndrome 9.9
122 lateral sinus thrombosis 9.9
123 sagittal sinus thrombosis 9.9
124 head injury 9.9
125 headache 9.9
126 spondyloarthropathy 1 9.9
127 annular erythema 9.9
128 arteries, anomalies of 9.9
129 breast cancer 9.9
130 factor viii deficiency 9.9
131 renal cell carcinoma, nonpapillary 9.9
132 rheumatoid arthritis 9.9
133 varicose veins 9.9
134 alopecia universalis congenita 9.9
135 iron-refractory iron deficiency anemia 9.9
136 lung cancer 9.9
137 lymphoma, hodgkin, classic 9.9
138 spondylocarpotarsal synostosis syndrome 9.9
139 hemophilia a 9.9
140 homocysteinemia 9.9
141 focal segmental glomerulosclerosis 1 9.9
142 lymphoma, non-hodgkin, familial 9.9
143 gastric cancer 9.9
144 protein z deficiency 9.9
145 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.9
146 autoimmune lymphoproliferative syndrome, type v 9.9
147 pulmonary hypertension 9.9
148 alopecia 9.9
149 anaplastic large cell lymphoma 9.9
150 coronary artery anomaly 9.9
151 diabetes mellitus 9.9
152 dilated cardiomyopathy 9.9
153 focal segmental glomerulosclerosis 9.9
154 glomerulonephritis 9.9
155 hematopoietic stem cell transplantation 9.9
156 hepatitis 9.9
157 hepatitis b 9.9
158 liver cirrhosis 9.9
159 pulmonary sarcoidosis 9.9
160 retinal vein occlusion 9.9
161 autosomal recessive pyridoxine-refractory sideroblastic anemia 2 9.9
162 cardiac arrest 9.9
163 microcytic anemia 9.9
164 hemopericardium 9.9
165 cardiac tamponade 9.9
166 portal vein thrombosis 9.9
167 iron deficiency anemia 9.9
168 choreatic disease 9.9
169 pure red-cell aplasia 9.9
170 neovascular glaucoma 9.9
171 pericarditis 9.9
172 melanoma 9.9
173 cholecystitis 9.9
174 iron metabolism disease 9.9
175 central retinal vein occlusion 9.9
176 retinal vascular disease 9.9
177 splenic infarction 9.9
178 hemoglobin c disease 9.9
179 skin carcinoma 9.9
180 hermansky-pudlak syndrome 9.9
181 pyoderma 9.9
182 infertility 9.9
183 paraplegia 9.9
184 spondylitis 9.9
185 monoclonal gammopathy of uncertain significance 9.9
186 pyoderma gangrenosum 9.9
187 pulmonary embolism 9.9
188 hemophilia 9.9
189 rere-related disorders 9.9
190 acquired hemophilia 9.9
191 acquired hemophilia a 9.9
192 bowenoid papulosis 9.9
193 broken heart syndrome 9.9
194 cold agglutinin disease 9.9
195 pdgfrb-associated chronic eosinophilic leukemia 9.9
196 plasmablastic lymphoma 9.9
197 polymyositis 9.9
198 xp22.3 microdeletion syndrome 9.9
199 trisomy 1q 9.9
200 bilateral massive adrenal hemorrhage 9.9
201 laryngeal adductor paralysis 9.9
202 multiple sclerosis 9.8
203 factor xii deficiency 9.8
204 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.8
205 congestive heart failure 9.8
206 ptosis 9.8
207 sensorineural hearing loss 9.8
208 protein-losing enteropathy 9.8
209 nephrotic syndrome 9.8
210 coronary artery vasospasm 9.8
211 iritis 9.8
212 optic nerve disease 9.8
213 gastroenteritis 9.8
214 protein c deficiency 9.8
215 eosinophilic gastroenteritis 9.8
216 coronary stenosis 9.8
217 compartment syndrome 9.8
218 neuropathy 9.8
219 eosinophilic enteropathy 9.8
220 fibrillary glomerulonephritis 9.8
221 primary polycythemia 9.8 ABL1 ASXL1 CALR CD177 EPO IL3
222 fibromuscular dysplasia 9.8
223 immunoglobulin alpha deficiency 9.8
224 blue toe syndrome 9.8
225 acromegaly 9.8

Graphical network of the top 20 diseases related to Essential Thrombocythemia:



Diseases related to Essential Thrombocythemia

Symptoms & Phenotypes for Essential Thrombocythemia

Human phenotypes related to Essential Thrombocythemia:

60 33 (showing 35, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 myocardial infarction 60 33 hallmark (90%) Very frequent (99-80%) HP:0001658
2 abnormal bleeding 60 33 hallmark (90%) Very frequent (99-80%) HP:0001892
3 transient ischemic attack 60 33 hallmark (90%) Very frequent (99-80%),Frequent (79-30%) HP:0002326
4 venous thrombosis 60 33 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0004936
5 paresthesia 60 33 hallmark (90%) Very frequent (99-80%),Frequent (79-30%) HP:0003401
6 amaurosis fugax 60 33 hallmark (90%) Very frequent (99-80%) HP:0100576
7 thrombocytosis 60 33 hallmark (90%) Very frequent (99-80%) HP:0001894
8 chest pain 60 33 hallmark (90%) Very frequent (99-80%),Frequent (79-30%) HP:0100749
9 prolonged bleeding time 60 33 hallmark (90%) Very frequent (99-80%) HP:0003010
10 abnormal platelet morphology 60 33 hallmark (90%) Very frequent (99-80%) HP:0011875
11 arterial thrombosis 60 33 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0004420
12 increased megakaryocyte count 60 33 hallmark (90%) Very frequent (99-80%) HP:0005513
13 hyperhidrosis 60 33 frequent (33%) Frequent (79-30%) HP:0000975
14 splenomegaly 60 33 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0001744
15 pruritus 60 33 frequent (33%) Frequent (79-30%) HP:0000989
16 headache 60 33 frequent (33%) Frequent (79-30%) HP:0002315
17 peripheral arterial stenosis 33 frequent (33%) HP:0004950
18 seizures 60 33 occasional (7.5%) Occasional (29-5%) HP:0001250
19 dysarthria 60 33 occasional (7.5%) Occasional (29-5%) HP:0001260
20 pulmonary arterial hypertension 60 33 occasional (7.5%) Occasional (29-5%) HP:0002092
21 myelodysplasia 60 33 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002863
22 acute myeloid leukemia 60 33 occasional (7.5%) Occasional (29-5%) HP:0004808
23 weight loss 60 33 occasional (7.5%) Occasional (29-5%) HP:0001824
24 visual field defect 60 33 occasional (7.5%) Occasional (29-5%) HP:0001123
25 vertigo 60 33 occasional (7.5%) Occasional (29-5%) HP:0002321
26 acute leukemia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002488
27 syncope 60 33 occasional (7.5%) Occasional (29-5%) HP:0001279
28 spontaneous abortion 60 33 occasional (7.5%) Occasional (29-5%) HP:0005268
29 myelofibrosis 60 33 occasional (7.5%) Occasional (29-5%) HP:0011974
30 chronic myelogenous leukemia 60 33 occasional (7.5%) Occasional (29-5%) HP:0005506
31 cerebral ischemia 60 Frequent (79-30%)
32 abnormality of the cerebral vasculature 60 Very frequent (99-80%)
33 abnormality of thrombocytes 60 Very frequent (99-80%)
34 abnormality of bone marrow cell morphology 60 Very frequent (99-80%)
35 occlusive vascular disease 60 Frequent (79-30%)

MGI Mouse Phenotypes related to Essential Thrombocythemia:

47 (showing 6, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.18 ABL1 ASXL1 CALR EPO JAK2 MPL
2 hematopoietic system MP:0005397 10.17 ABL1 ASXL1 CD177 EPO JAK2 MPL
3 homeostasis/metabolism MP:0005376 10.03 ABL1 ASXL1 CALR EPO JAK2 MPL
4 immune system MP:0005387 10 ABL1 ASXL1 CD177 EPO JAK2 MPL
5 liver/biliary system MP:0005370 9.61 ABL1 ASXL1 EPO JAK2 SELP STAT5B
6 mortality/aging MP:0010768 9.4 ABL1 ASXL1 CALR EPO JAK2 MPL

Drugs & Therapeutics for Essential Thrombocythemia

Drugs for Essential Thrombocythemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 278, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxyurea Approved Phase 4,Phase 3,Phase 2,Not Applicable 127-07-1 3657
2
Anagrelide Approved Phase 4,Phase 3,Phase 2 68475-42-3 2182
3
tannic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1401-55-4
4
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
5
Lactitol Investigational Phase 4,Phase 2,Phase 3 585-88-6, 585-86-4 493591
6 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
7 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
8 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
9
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
10
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 55-98-1 2478
11
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
12
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 38904 498142
13
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
14
Aspirin Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-78-2 2244
15
Peginterferon alfa-2a Approved, Investigational Phase 3,Phase 2,Phase 1 198153-51-4 5360545
16
Pomalidomide Approved Phase 3,Phase 2,Phase 1 19171-19-8
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
18
Dalteparin Approved Phase 3 9005-49-6
19
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
20
Ondansetron Approved Phase 3,Phase 1,Phase 2,Not Applicable 99614-02-5 4595
21
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
22
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
23
Caspofungin Approved Phase 3,Phase 2 162808-62-0, 179463-17-3 2826718 468682
24
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
25
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
26
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
27
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
28
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
29
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1 148-82-3 460612 4053
30
Danazol Approved Phase 3,Phase 2 17230-88-5 28417
31
Cytarabine Approved, Experimental, Investigational Phase 3,Phase 2,Phase 1 147-94-4, 65-46-3 6253
32
Peginterferon alfa-2b Approved Phase 3 215647-85-1, 99210-65-8
33
Mercaptopurine Approved Phase 3 50-44-2 667490
34
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
35
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
36 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
37 Anesthetics Phase 3
38 Anesthetics, Dissociative Phase 3
39 Anesthetics, Intravenous Phase 3
40 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
41 Excitatory Amino Acid Antagonists Phase 3
42 Central Nervous System Depressants Phase 3,Phase 1,Phase 2,Not Applicable
43 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
44 Analgesics Phase 3,Phase 2,Phase 1,Not Applicable
45 Anesthetics, General Phase 3
46 Excitatory Amino Acids Phase 3
47 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
48 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
49 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
51 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
52 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
53 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1,Not Applicable
54 Alkylating Agents Phase 2, Phase 3,Phase 1,Not Applicable
55 Antilymphocyte Serum Phase 2, Phase 3,Phase 1,Not Applicable
56 Antimetabolites Phase 2, Phase 3,Phase 1,Not Applicable
57 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 1,Not Applicable
58 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
59 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Not Applicable
60 interferons Phase 3,Phase 2,Phase 1
61 Interferon-alpha Phase 3,Phase 2,Phase 1
62 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 2,Not Applicable
63 Antipyretics Phase 3,Phase 2,Not Applicable
64 Cyclooxygenase Inhibitors Phase 3,Phase 2,Not Applicable
65 Analgesics, Non-Narcotic Phase 3,Phase 2,Phase 1,Not Applicable
66 Interferon alpha-2 Phase 3,Phase 2,Phase 1
67 Janus Kinase Inhibitors Phase 3,Phase 2,Phase 1
68 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
69 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
70 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
71 Narcotics Phase 3,Not Applicable
72 Analgesics, Opioid Phase 3,Not Applicable
73 Liver Extracts Phase 3,Phase 1
74 Adjuvants, Anesthesia Phase 3
75 Cola Phase 3,Phase 1,Phase 2
76 Hormones Phase 3,Phase 2,Phase 1
77 Anticoagulants Phase 3,Phase 1,Phase 2
78 Heparin, Low-Molecular-Weight Phase 3
79 calcium heparin Phase 3
80 Serotonin Agents Phase 3,Not Applicable
81 Serotonin Antagonists Phase 3,Not Applicable
82 Autonomic Agents Phase 3,Phase 2,Phase 1,Not Applicable
83 Psychotropic Drugs Phase 3,Not Applicable
84 Antiemetics Phase 3,Phase 2,Phase 1,Not Applicable
85 Anti-Anxiety Agents Phase 3,Not Applicable
86 Antipsychotic Agents Phase 3,Not Applicable
87 Antipruritics Phase 3,Not Applicable
88 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
89 Tranquilizing Agents Phase 3,Not Applicable
90 Antiprotozoal Agents Phase 3,Phase 1,Phase 2
91 Antifungal Agents Phase 3,Phase 2,Phase 1,Not Applicable
92 Antiparasitic Agents Phase 3,Phase 1,Phase 2
93 Liposomal amphotericin B Phase 3
94 Chlorpheniramine, phenylpropanolamine drug combination Phase 3,Not Applicable
95 Antitussive Agents Phase 3,Not Applicable
96 Respiratory System Agents Phase 3,Phase 2,Phase 1,Not Applicable
97 Mitogens Phase 3,Phase 1,Phase 2
98 N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide Phase 3,Phase 2,Phase 1
99 Topoisomerase Inhibitors Phase 2, Phase 3,Phase 1,Not Applicable
100 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 1
101 Etoposide phosphate Phase 2, Phase 3,Phase 1
102 glucocorticoids Phase 3,Phase 2,Phase 1
103 Androgens Phase 3
104
Serotonin Investigational, Nutraceutical Phase 3,Not Applicable 50-67-9 5202
105
Vorinostat Approved, Investigational Phase 2,Phase 1 149647-78-9 5311
106
Panobinostat Approved, Investigational Phase 1, Phase 2,Phase 2 404950-80-7 6918837
107
Lenograstim Approved, Investigational Phase 2,Phase 1,Not Applicable 135968-09-1
108
leucovorin Approved Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
109
Tacrolimus Approved, Investigational Phase 2,Phase 1,Not Applicable 104987-11-3 6473866 445643 439492
110
Methotrexate Approved Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
111
Sargramostim Approved, Investigational Phase 1, Phase 2 123774-72-1, 83869-56-1
112
Mycophenolic acid Approved Phase 1, Phase 2,Phase 2,Not Applicable 24280-93-1 446541
113
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
114
Prednisone Approved, Vet_approved Phase 2,Phase 1 53-03-2 5865
115
Lenalidomide Approved Phase 2 191732-72-6 216326
116
Mirabegron Approved Phase 2 223673-61-8 9865528
117
Idarubicin Approved Phase 2 58957-92-9 42890
118
Verapamil Approved Phase 2 52-53-9 2520
119
Vidarabine Approved, Investigational Phase 2,Phase 1 24356-66-9 21704 32326
120
Aldesleukin Approved Phase 1, Phase 2,Phase 2 110942-02-4, 85898-30-2
121
alemtuzumab Approved, Investigational Phase 1, Phase 2,Phase 2 216503-57-0
122
Phenytoin Approved, Vet_approved Phase 1, Phase 2 57-41-0 1775
123
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
124
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
125
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
126
Decitabine Approved, Investigational Phase 2,Phase 1 2353-33-5 451668
127
Daunorubicin Approved Phase 2 20830-81-3 30323
128
Azacitidine Approved, Investigational Phase 2,Phase 1 320-67-2 9444
129
Topotecan Approved, Investigational Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
130
Methylprednisolone Approved, Vet_approved Phase 2,Phase 1 83-43-2 6741
131
Methylprednisolone hemisuccinate Approved Phase 2,Phase 1 2921-57-5
132
Prednisolone phosphate Approved, Vet_approved Phase 2,Phase 1 302-25-0
133
Prednisolone Approved, Vet_approved Phase 2,Phase 1 50-24-8 5755
134
Levoleucovorin Approved, Investigational Phase 2,Phase 1 68538-85-2
135
Pembrolizumab Approved Phase 2 1374853-91-4
136
Venetoclax Approved, Investigational Phase 1, Phase 2 1257044-40-8 49846579
137
Sodium Citrate Approved, Investigational Phase 2 68-04-2
138
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 5284616 6436030
139
nivolumab Approved Phase 2 946414-94-4
140
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037